Population Pharmacokinetic Model of Amikacin and Vancomycin in Critically Ill Patients

University Clinical Centre of Republic of Srpska

Status: Enrolling

Conditions: Sepsis

Treatments: Device: Cytosorb® and Oxiris® adsorbents

Study type: Observational

Funder types: Other

Identifiers

NCT06261164

01-19-373- 2/23

Details and patient eligibility

About

The object of the scientific research is the characterization of the pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.

Enrollment: 20 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of SIRS, sepsis and/or septic shock,
• older than 18 years, who are being treated with amikacin and/or vancomycin,
• length of use of adsorbent at least 12 hours.

Exclusion criteria

• contraindication for hemodiafiltration with adsorbents,
• patients under the age of 18,
• terminal cancer patients.

Trial design

20 participants in 2 patient groups

Patients on hemodiafiltration with Cytosorb®

Treatment:

Device: Cytosorb® and Oxiris® adsorbents

Patients on hemodiafiltration with Oxiris®

Treatment:

Device: Cytosorb® and Oxiris® adsorbents